Stoke Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:STOK Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
09 Dec 24	SellUS$88,158	Edward Kaye	Individual	6,786	US$12.99
09 Dec 24	SellUS$20,164	Jonathan Allan	Individual	1,552	US$12.99
09 Dec 24	SellUS$33,596	Barry Ticho	Individual	2,586	US$12.99
06 Dec 24	SellUS$78,837	Edward Kaye	Individual	6,170	US$12.78
06 Dec 24	SellUS$123,891	Jonathan Allan	Individual	9,696	US$12.78
06 Dec 24	SellUS$178,182	Barry Ticho	Individual	13,945	US$12.78
19 Sep 24	SellUS$27,221,875	Skorpios Trust	Company	1,937,500	US$14.05
17 Apr 24	SellUS$41,760,000	Skorpios Trust	Company	3,600,000	US$11.60

Insider Trading Volume

Insider Buying: STOK insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of STOK?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	2,478,602	4.05%
Hedge Funds	13,734,237	22.4%
Institutions	45,023,381	73.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.6%.

Top Shareholders

Top 25 shareholders own 106.38% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
16.8%	Skorpios Trust	8,906,181	US$104.0m	-17.9%	99.85%
10.5%	BlackRock, Inc.	5,570,150	US$65.1m	2.98%	no data
9.79%	Lynx1 Capital Management LP	5,187,191	US$60.6m	0.04%	24.9%
8.9%	Redmile Group, LLC	4,713,509	US$55.1m	-0.16%	3.01%
8.78%	RTW Investments, LP	4,652,285	US$54.3m	10.1%	0.77%
8.25%	Baker Bros. Advisors LP	4,368,443	US$51.0m	0%	0.5%
7.92%	Morgan Stanley, Investment Banking and Brokerage Investments	4,197,124	US$49.0m	21.2%	0.01%
6.13%	Cowen Inc,Private Banking and Investment Banking Investments	3,244,498	US$37.9m	-3.6%	1.03%
5.21%	The Vanguard Group, Inc.	2,759,247	US$32.2m	2.66%	no data
3.54%	Seth Harrison	1,875,313	US$21.9m	0%	no data
3.26%	State Street Global Advisors, Inc.	1,728,888	US$20.2m	8.62%	no data
3.15%	Marshall Wace LLP	1,670,733	US$19.5m	43.9%	0.03%
2.48%	Assenagon Asset Management S.A.	1,312,479	US$15.3m	-10.6%	0.03%
2.45%	Goldman Sachs Group, Investment Banking and Securities Investments	1,299,385	US$15.2m	2.58%	0.01%
1.64%	Geode Capital Management, LLC	870,831	US$10.2m	9.65%	no data
1.22%	Granahan Investment Management, LLC	644,970	US$7.5m	7.78%	0.28%
0.91%	BioImpact Capital LLC	479,452	US$5.6m	0%	0.95%
0.87%	Deutsche Asset & Wealth Management	462,475	US$5.4m	2,790%	no data
0.81%	Cormorant Asset Management, LP	427,163	US$5.0m	0%	0.27%
0.76%	Adrian Krainer	404,718	US$4.7m	0%	no data
0.64%	Northern Trust Global Investments	339,153	US$4.0m	20%	no data
0.62%	Jane Street Group, LLC, Asset Management Arm	330,442	US$3.9m	338%	0.01%
0.61%	FMR LLC	321,918	US$3.8m	-19.1%	no data
0.6%	Charles Schwab Investment Management, Inc.	316,134	US$3.7m	9.29%	no data
0.5%	Dimensional Fund Advisors LP	265,010	US$3.1m	38.5%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 08:01
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stoke Therapeutics, Inc. is covered by 17 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Gregory Harrison	BofA Global Research
Thomas Shrader	BTIG
Michelle Gilson	Canaccord Genuity